Related Experiment Video
Updated: Mar 16, 2026

Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
Published on: September 20, 2018
Transcriptional regulation of E-cadherin by small activating RNA: A new double-stranded RNA
Zhiming Wu1, Yan Li2, Zhiyong Li1
1Department of Urology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, P.R. China.
Abstract:
Recent studies have reported that chemically synthesized small activating RNA (saRNA) targeting the promoter regions of a gene can activate its expression in different cell lines. This technique can be a powerful therapeutic method for diseases caused by complete inactivation or reduced expression of specific genes. E-cadherin is a typical tumor suppressor gene. Loss of E-cadherin mediates the transition from benign lesions to invasive, metastatic cancer. In this study, several 21-nt small double-stranded RNAs (dsRNAs) targeting the promoter regions of human E-cadherin were designed and synthesized and the features of their function were investigated to study the regulatory role of dsRNA on E-cadherin expression. A new saRNA (dsEcad‑661) that can enhance E-cadherin expression by targeting non-coding regulatory regions in gene promoters was identified. Using dsRNA with modified base quantity and cholesterol-conjugated dsRNA, we found the antisense strand may be the guide strand of saRNA in the upregulation of E-cadherin. These findings provide several important pieces of evidence that may improve understanding of the function of saRNA and may promote its development for clinical application.
Insights
Small activating RNA (saRNA) can enhance gene expression by targeting promoter regions. Researchers identified a novel saRNA, dsEcad-661, that upregulates E-cadherin, a tumor suppressor gene, offering potential therapeutic applications.
Area of Science:
- Molecular Biology
- RNA Therapeutics
- Cancer Genetics
Background:
- Small activating RNA (saRNA) represents a novel therapeutic strategy for diseases linked to gene silencing.
- E-cadherin, a crucial tumor suppressor, plays a vital role in preventing cancer progression and metastasis.
- Dysregulation of E-cadherin expression is a hallmark of many cancers, driving disease advancement.
Purpose of the Study:
- To investigate the potential of small double-stranded RNAs (dsRNAs) to modulate E-cadherin expression.
- To identify and characterize saRNAs targeting the promoter regions of the human E-cadherin gene.
- To elucidate the mechanism underlying saRNA-mediated E-cadherin upregulation.
Main Methods:
- Design and synthesis of multiple 21-nucleotide (nt) dsRNAs targeting human E-cadherin promoter regions.
- Functional assessment of synthesized dsRNAs for their ability to enhance E-cadherin expression.
- Investigation of saRNA mechanism using modified dsRNAs (base quantity alterations, cholesterol conjugation).
Main Results:
- Identification of a novel saRNA, dsEcad-661, capable of significantly enhancing E-cadherin expression.
- Demonstration that dsEcad-661 targets non-coding regulatory regions within the E-cadherin gene promoter.
- Evidence suggesting the antisense strand of saRNA acts as the guide strand in E-cadherin upregulation.
Conclusions:
- The study successfully identified a functional saRNA (dsEcad-661) for enhancing E-cadherin expression.
- Findings provide insights into the mechanism of saRNA action, highlighting the role of the antisense strand.
- This research supports the potential of saRNA technology for therapeutic applications in cancers characterized by E-cadherin loss.
More Related Videos
Related Concept Videos
RNA Polymerase II Accessory Proteins
Co-activators and Co-repressors
Cadherins in Tissue Organization
Cell Sorting During Development
Cell sorting plays an...
Regulation of Expression at Multiple Steps
Translational Regulation
Master Transcription Regulators

